{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:27:52Z","timestamp":1759411672149},"reference-count":26,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vaccine.2014.03.076","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T12:34:40Z","timestamp":1400070880000},"page":"5131-5139","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anthrax vaccine adsorbed: Further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed"],"prefix":"10.1016","volume":"32","author":[{"given":"Phillip R.","family":"Pittman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Cavicchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Barrera-Oro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ranadive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.03.076_bib0005","unstructured":"Initial program announcement press briefing \u3008http:\/\/www.defenselink.mil\/news\/Dec1997\/x12181997 1215mfp.html, & see full scale announcement press briefing: http:\/\/www.defenselink.mil\/news\/May1998\/x05281998 0522mfp.html\u3009"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0010","unstructured":"Executive Order 13139\u2014Improving Health Protection of Military Personnel Participating in Particular Military Operations. [June 13, 2007]. Available at \u3008http:\/\/www.archives.gov\/federal-register\/executive-orders\/1999.html\u3009; 1999."},{"key":"10.1016\/j.vaccine.2014.03.076_bib0015","series-title":"Implementation of the anthrax vaccine immunization program (AVIP) [Memorandum]","author":"Chu","year":"2006"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0020","unstructured":"Biological Products; Bacterial vaccines and toxoids; implementation of efficacy review; anthrax vaccine adsorbed; Final Order. FDA. Federal Register. 70; 242; 75180, Dec 19, 2005."},{"key":"10.1016\/j.vaccine.2014.03.076_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4172\/2157-2526.1000107","article-title":"Anthrax Bioterrorism: prevention, diagnosis and management strategies","volume":"2","author":"Fowler","year":"2011","journal-title":"J Bioterr Biodef"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0030","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0264-410X(00)00174-2","article-title":"Anthrax vaccine: increasing intervals between the first 2 doses enhances antibody response in humans","volume":"19","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0040","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0045","series-title":"The anthrax vaccine. Is it safe? Does it work?","article-title":"Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-up Agency","author":"Institute of Medicine","year":"2002"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2014.03.076_bib0050","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0264-410X(02)00172-X","article-title":"Aluminum-containing vaccine associated adverse events: role of route of administration and gender","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/j.vaccine.2014.03.076_bib0055","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.vaccine.2006.01.054","article-title":"Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series","volume":"24","author":"Pittman","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2014.03.076_bib0060","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.vaccine.2006.11.005","article-title":"The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine","volume":"25","author":"Lininger","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2014.03.076_bib0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.vaccine.2007.11.085","article-title":"Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by Anthrax Vaccine Adsorbed (AVA) among U.S. military personnel","volume":"26","author":"Singer","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.03.076_bib0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1128\/CVI.13.2.208-213.2006","article-title":"Neutralizing antibodies and persistence of immunity following anthrax vaccination","volume":"13","author":"Hanson","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2014.03.076_bib0075","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0080","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months, a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"issue":"RR-6","key":"10.1016\/j.vaccine.2014.03.076_bib0085","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunizations Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0090","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0264-410X(02)00058-0","article-title":"Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0095","doi-asserted-by":"crossref","first-page":"5009-5014","DOI":"10.1016\/j.vaccine.2013.08.086","article-title":"Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity","volume":"31","author":"Pittman","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0100","series-title":"Anthrax vaccine adsorbed","author":"Michigan department of Public Health","year":"1978"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0105","series-title":"Biologics license application supplement approval letter","author":"Sun","year":"2008"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0110","series-title":"BioThrax\u00ae (Anthrax Vaccine Adsorbed)","author":"Emergent BioSolutions","year":"2012"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0115","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive and quantitative enzyme-linked immunosorbent assay for human immunolglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0125","series-title":"SAS\/STAT 9.4 user's guide","author":"SAS Institute Inc.","year":"2011"},{"key":"10.1016\/j.vaccine.2014.03.076_bib0130","first-page":"9","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax accine adsorbed on immunological response and safety profile: a randomized trial","volume":"101","author":"Wright","year":"2014","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T05:51:33Z","timestamp":1538632293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14004575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":26,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0264410X14004575"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.076","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anthrax vaccine adsorbed: Further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}